Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type 1 diabetes.
Date
2011-09Journal
Diabetic medicine : a journal of the British Diabetic AssociationType
Research Support, Non-U.S. Gov'tPublisher
WileyDOI
10.1111/j.1464-5491.2011.03287.xRights
Archived with thanks to Diabetic medicine : a journal of the British Diabetic AssociationMetadata
Show full item recordAbstract
Maturity-onset diabetes of the young is a monogenic form of familial, young-onset diabetes. It is rare (∼1% diabetes) and may be misdiagnosed as Type 1 diabetes and inappropriately treated with insulin. Type 1 diabetes is characterized by the presence of islet autoantibodies, including glutamate decarboxylase (GAD) and islet antigen-2 (IA-2) antibodies. The prevalence of islet autoantibodies is unknown in maturity-onset diabetes of the young and may have the potential to differentiate this form of diabetes from Type 1 diabetes. The aim of this study was to determine the prevalence of GAD and IA-2 antibodies in patients with maturity-onset diabetes of the young and Type 1 diabetes.